Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Toxic effect type:
dose-dependent

Effects on fertility

Description of key information

Toxicity to Reproduction (Screening): In accordance with Column 2 of ANNEX VIII of the REACH regulation, screening for reproductive/developmental toxicity study does not need to be conducted as a pre-natal developmental toxicity study is available.


Extended one-generation reproductive toxicity: In accordance with Column 2 of ANNEX IX of the REACH regulation, a extended one-generation reproductive toxicity study does not need not to be conducted as the existing repeated dose toxicity study does not indicate adverse effects on reproductive organs or tissues.

Link to relevant study records

Referenceopen allclose all

Endpoint:
extended one-generation reproductive toxicity - basic test design (Cohorts 1A, and 1B without extension)
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
the extended one-generation reproductive toxicity study does not need to be conducted because there are no results from available repeated dose toxicity studies that indicate adverse effects on reproductive organs or tissues, or reveal other concerns in relation with reproductive toxicity
Endpoint:
screening for reproductive / developmental toxicity
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Reason / purpose for cross-reference:
data waiving: supporting information
Reason / purpose for cross-reference:
data waiving: supporting information
Reason / purpose for cross-reference:
data waiving: supporting information
Reproductive effects observed:
not specified
Effect on fertility: via oral route
Endpoint conclusion:
no study available
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

Toxicity to Reproduction (Screening): In accordance with Column 2 of ANNEX VIII of the REACH regulation, screening for reproductive/developmental toxicity study does not need to be conducted as a pre-natal developmental toxicity study is available.


Extended one-generation reproductive toxicity: In accordance with Column 2 of ANNEX IX of the REACH regulation, a extended one-generation reproductive toxicity study does not need not to be conducted as the existing repeated dose toxicity study does not indicate adverse effects on reproductive organs or tissues.

Effects on developmental toxicity

Description of key information

Pre-natal developmental toxicity study (rat, oral):
NOAEL for maternal/foetotoxicity toxicity: 600 mg/kg bw/day.
NOAEL for embryotoxicity/teratogenicity: 600 mg/kg bw/day. 

Link to relevant study records

Referenceopen allclose all

Endpoint:
developmental toxicity
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Justification for type of information:
Read-across justification attached below.
Reason / purpose for cross-reference:
read-across source
Species:
rat
Strain:
CD-1
Clinical signs:
no effects observed
Mortality:
no mortality observed
Body weight and weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
Compared to the control group there was a reduction in maternal weight gain in all treated groups.
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
not examined
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Number of abortions:
not specified
Pre- and post-implantation loss:
not specified
Total litter losses by resorption:
not specified
Early or late resorptions:
not specified
Dead fetuses:
not specified
Changes in pregnancy duration:
not specified
Changes in number of pregnant:
not specified
Dose descriptor:
NOAEL
Effect level:
>= 600 mg/kg bw/day (nominal)
Basis for effect level:
behaviour (functional findings)
body weight and weight gain
mortality
Abnormalities:
no effects observed
Fetal body weight changes:
effects observed, non-treatment-related
Reduction in number of live offspring:
no effects observed
Changes in sex ratio:
not specified
Changes in litter size and weights:
no effects observed
Changes in postnatal survival:
no effects observed
External malformations:
effects observed, non-treatment-related
Description (incidence and severity):
No malformations were observed in the control, 50 or 300 mg/kg/day groups. One malformation,
meningocele, was observed in one fetus from one litter in the 600 mg/kg/day. The number of
fetuses and litters with genetic or developmental variations in all treated groups was comparable to the control group.
Skeletal malformations:
no effects observed
Visceral malformations:
no effects observed
Dose descriptor:
NOAEL
Effect level:
>= 600 mg/kg bw/day (nominal)
Basis for effect level:
reduction in number of live offspring
fetal/pup body weight changes
external malformations
skeletal malformations
visceral malformations
Abnormalities:
no effects observed
Developmental effects observed:
no
Conclusions:
Treatment with 4-methylstyrene did not produce a teratogenic response when administered orally to pregnant rats at a dosage level of 600 mg/kg/day or less.The target substance is also predicted to be not teratogenic.
Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment
Qualifier:
according to guideline
Guideline:
other: Not referenced
GLP compliance:
yes
Limit test:
no
Species:
rat
Strain:
CD-1
Details on test animals or test system and environmental conditions:
Sexually mature, virgin female Charles River COBS CD rats (approximately 12 weeks old).
Route of administration:
oral: gavage
Vehicle:
olive oil
Remarks:
Dose volume of 5 mL/kg
Details on exposure:
Beginning on day 6 of gestation and continuing daily through day 19 of gestation, the test substance was suspended in corn oil and administered by oral gavage (volume, 5.0 ml/kg) to pregnant females at a single daily dose of 50, 300, and 600 mg/kg/day. A control group received the vehicle only on comparable regimen at a volume of 5 ml/kg.
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
Sexually mature, virgin female Charles River COBS CD rats (approximately 12 weeks old) were mated in 1:1 with males in sufficient numbers to assign a minimum of 25 pregnant animals per group.
Duration of treatment / exposure:
seven days/week
Frequency of treatment:
Once daily
Duration of test:
20 days after gestation
Dose / conc.:
600 mg/kg bw/day (nominal)
Dose / conc.:
300 mg/kg bw/day (nominal)
Dose / conc.:
50 mg/kg bw/day (nominal)
No. of animals per sex per dose:
25 females
Control animals:
yes, concurrent vehicle
Details on study design:
Sexually mature, virgin female Charles River COBS CD rats (approximately 12 weeks old) were mated in 1:1 with males in sufficient numbers to assign a minimum of 25 pregnant animals per group. Beginning on day 6 of gestation and continuing daily through day 19 of gestation, the test substance was suspended in vehicle and administered by oral gavage (volume, 5.0 ml/kg) to pregnant females at a single daily dose of 50, 300, and 600 mg/kg/day. A control group received the vehicle only on a comparable regimen at a volume of 5 ml/kg.
Maternal examinations:
mortality(Prior to treatment and GD 6 to 19)
appearance and behavior(Prior to treatment )
clinical signs (GD 6 to 19)
body weights (GD 0 to 20)
Ovaries and uterine content:
organ weight, the number and location of viable and nonviable fetuses, early and late resorptions, and the number of total implantations and corpora lutea
Fetal examinations:
weight, examined for external malformations and variations, including the palate and eyes. Each
fetus was externally sexed and individually numbered and tagged for identification. Approximately one-half of the fetuses were placed in Bouin’s fixative for subsequent visceral examination by razor-blade sectioning. The remaining one-half of the fetuses were fixed in alcohol, macerated in potassium hydroxide and stained with Alizarin Red S for subsequent skeletal examination.
Clinical signs:
no effects observed
Mortality:
no mortality observed
Body weight and weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
Compared to the control group there was a reduction in maternal weight gain in all treated groups.
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
not examined
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Number of abortions:
not specified
Pre- and post-implantation loss:
not specified
Total litter losses by resorption:
not specified
Early or late resorptions:
not specified
Dead fetuses:
not specified
Changes in pregnancy duration:
not specified
Changes in number of pregnant:
not specified
Dose descriptor:
NOAEL
Effect level:
>= 600 mg/kg bw/day (nominal)
Basis for effect level:
behaviour (functional findings)
body weight and weight gain
mortality
Abnormalities:
no effects observed
Fetal body weight changes:
effects observed, non-treatment-related
Reduction in number of live offspring:
no effects observed
Changes in sex ratio:
not specified
Changes in litter size and weights:
no effects observed
Changes in postnatal survival:
no effects observed
External malformations:
effects observed, non-treatment-related
Description (incidence and severity):
No malformations were observed in the control, 50 or 300 mg/kg/day groups. One malformation, meningocele, was observed in one fetus from one litter in the 600 mg/kg/day. The number of
fetuses and litters with genetic or developmental variations in all treated groups was comparable to the control group.
Skeletal malformations:
no effects observed
Visceral malformations:
no effects observed
Dose descriptor:
NOAEL
Effect level:
>= 600 mg/kg bw/day (nominal)
Basis for effect level:
reduction in number of live offspring
fetal/pup body weight changes
external malformations
skeletal malformations
visceral malformations
Abnormalities:
no effects observed
Developmental effects observed:
no
Conclusions:
Under the study conditions, the NOAEL for teratogenicity was established at 600 mg/kg bw/day.
Executive summary:

A study was conducted to determine the teratogenic potential of the read across substance, 4-methylstyrene. Groups of 25 pregnant Charles River COBS CD rats were given the test substance by oral gavage (volume, 5.0 ml/kg), from Gestation Day (GD) 6 to 19 at a single daily dose of 50, 300, and 600 mg/kg/day. A control group received the vehicle only, olive oil, at a dose volume of 5 mL/kg bw.


There were no mortalities or clinical signs in the maternal groups. Compared to controls, there was a reduction in maternal weight gain in all treated groups and this was considered not statistically significant. Fetal weights in all treated groups were also significantly lower than the controls. However, this may have been the results of an unusually high control value for fetal weight, above the normal background range of the laboratory. There were no biologically meaningful differences in the mean number of corpora lutea, total implantations, early or late resorptions, post implantation loss, viable fetuses, fetal sex distribution, mean fetal body weight or number of fetuses (and litters) with malformations. 


Under the study conditions, the NOAEL for teratogenicity was established at 600 mg/kg bw/day. 

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment
Qualifier:
according to guideline
Guideline:
other: Not referenced
GLP compliance:
not specified
Limit test:
yes
Specific details on test material used for the study:
no available
Species:
rat
Strain:
Sprague-Dawley
Details on test animals or test system and environmental conditions:
Female
Route of administration:
intraperitoneal
Vehicle:
corn oil
Details on exposure:
Female rats injected intraperitoneally with the test chemical dissolved or suspended in corn oil at 250 mg/kg (MTD, maximum tolerated dose) .
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
After the MTD determination, young adult female Sprague-Dawley rats (250-300 g) were caged with breeder males of the same strain. The females were examined daily for the presence of sperm in a vaginal lavage. The day sperm was detected was designated as day 1 of gestation. Inseminated females were randomly assigned to treatment and control groups.
Duration of treatment / exposure:
15days
Frequency of treatment:
daily for 15 days
Dose / conc.:
250 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
10-15
Details on study design:
Young adult female Sprague-Dawley rats (250-300 g) were caged with breeder males of the same strain. The females were examined daily for the presence of sperm in a vaginal lavage. The day sperm was detected was designated as day 1 of gestation. Inseminated females were randomly assigned to treatment and control groups. Treatment began on day 1 of gestation and continued through day 15. Controls were injected intraperitoneally with corn oil, while the test group received the test chemical in corn oil at the MTD (250 mg/kg). Each group was composed of 10-15 inseminated females individually housed in stainless steel wire mesh cages with free access to food and water.
On day 21 of gestation, the females were killed by decapitation and the uterine contents were examined. The individual fetuses were weighed, measured for crown-rump length, sexed, and examined for externally visible malformations. One-half to two-thirds of each litter was preserved in Bouin’s fluid for internal examination by the Wilson method of free-hand razor-blade sectioning, and the balance of each litter was preserved in ethanol for clearing and skeletal staining with alizarin red. The internal organs of the maternal rats were examined grossly, and the brain, heart, lungs, liver, spleen, kidneys, adrenals, and ovaries were weighed and then preserved in 10% formalin for histopathological examination.
Ovaries and uterine content:
On day 21 of gestation, the females were killed by decapitation and the uterine contents were examined.
Fetal examinations:
The individual fetuses were weighed, measured for crown-rump length, sexed, and examined for externally visible malformations;
internal examination;
skeletal examination.
Statistics:
Fisher’s exact test
Clinical signs:
not examined
Mortality:
not examined
Body weight and weight changes:
not examined
Food efficiency:
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not specified
Gross pathological findings:
not examined
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
effects observed, non-treatment-related
Histopathological findings: neoplastic:
not specified
Number of abortions:
not examined
Pre- and post-implantation loss:
not examined
Total litter losses by resorption:
not examined
Early or late resorptions:
not examined
Dead fetuses:
not examined
Changes in pregnancy duration:
not examined
Changes in number of pregnant:
not examined
Details on maternal toxic effects:
The incidence of resorptions was significantly increased (p<0.05), No teratogenic effects were observed. In addition, no treatment-related histopathological changes were observed in maternal tissues.
Dose descriptor:
LOAEL
Effect level:
250 mg/kg bw/day (nominal)
Basis for effect level:
early or late resorptions
Abnormalities:
no effects observed
Fetal body weight changes:
not specified
Reduction in number of live offspring:
not examined
Changes in sex ratio:
effects observed, treatment-related
Description (incidence and severity):
fetal sex ratio was significantly altered (p<0.05) with a deficit of female fetuses
Changes in litter size and weights:
not examined
Anogenital distance of all rodent fetuses:
not examined
Changes in postnatal survival:
not examined
External malformations:
not specified
Skeletal malformations:
not specified
Visceral malformations:
not specified
Dose descriptor:
LOAEL
Effect level:
250 mg/kg bw/day (actual dose received)
Basis for effect level:
changes in sex ratio
Abnormalities:
no effects observed
Developmental effects observed:
no
Conclusions:
The substance is non-teratogenic.
Executive summary:

In the pre-natal developmental toxicity study( Hardin BD,1981),female Sprague-Dawley rats was daily intraperitoneally administrated with the test chemical dissolved or suspended in corn oil at 250 mg/kg for 15 days.


The incidence of resorptions was significantly increased (p<0.05), and the fetal sex ratio was significantly altered (p<0.05) with a deficit of female fetuses. No teratogenic effects were observed. In addition, no treatment-related histopathological changes were observed in maternal tissues.


The substance is non-teratogenic.

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
600 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
The key study was well documented, and meets generally accepted scientific principles and was assigned a Klimisch score of 2. The overall quality of the database is high.
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

A study was conducted to determine the teratogenic potential of the read across substance, 4-methylstyrene. Groups of 25 pregnant Charles River COBS CD rats were given the test substance by oral gavage (volume, 5.0 ml/kg), from Gestation Day (GD) 6 to 19 at a single daily dose of 50, 300, and 600 mg/kg/day. A control group received the vehicle only, olive oil, at a dose volume of 5 mL/kg bw.


There were no mortalities or clinical signs in the maternal groups. Compared to controls, there was a reduction in maternal weight gain in all treated groups and this was considered not statistically significant. Fetal weights in all treated groups were also significantly lower than the controls. However, this may have been the results of an unusually high control value for fetal weight, above the normal background range of the laboratory. There were no biologically meaningful differences in the mean number of corpora lutea, total implantations, early or late resorptions, post implantation loss, viable fetuses, fetal sex distribution, mean fetal body weight or number of fetuses (and litters) with malformations. 


Under the study conditions, the NOAEL for teratogenicity was established at 600 mg/kg bw/day. 

Justification for classification or non-classification

Based on the available information in the dossier, the substance Vinyltoluene does not need to be classified for reproductive toxicity when the criteria outlined in Annex I of 1272/2008/ EC are applied.

Additional information